Selexys Pharmaceuticals Corporation

Selexys Pharmaceuticals Corporation is a biopharmaceutical firm focused on developing innovative therapies for hematological conditions, particularly targeting sickle cell disease through advanced molecular technology. Selexys Pharmaceuticals Corporation develops investigational therapies aimed at treating hematological disorders. Headquartered in Oklahoma City, US, the company has engaged in strategic funding activities, with the latest funding round completed in November 2016, raising USD 8. 740 mn.

In the same month, Novartis International AG announced plans to acquire Selexys for up to USD 665 million, inclusive of acquisition and milestone payments. Selexys specializes in innovative biopharmaceutical products for hematological conditions, particularly focusing on sickle cell disease. Their primary product is an investigational therapy that employs advanced molecular technology to alleviate the frequency of painful crises in patients. The therapy interacts with specific cellular pathways to mitigate debilitating symptoms, thereby improving patients' quality of life.

The company serves a wide range of healthcare providers, including hospitals and specialty clinics, across the United States, Europe, and select Asian markets. Selexys generates revenue through direct-to-consumer sales and partnerships with healthcare providers and research institutions. Its business model is based on offering its investigational therapy via clinical trials and subsequent commercialization, ensuring patient access. Revenue comes from one-time therapy purchases and ongoing agreements with healthcare systems for patient access programs.

Collaborations with pharmaceutical companies for co-development also contribute to its revenue, although specific pricing details remain undisclosed. Selexys Pharmaceuticals Corporation plans to utilize its recent funding obtained in November 2016 to enhance its product development and market expansion efforts. The company aims to advance its investigational therapy towards commercialization, with potential new products designed to meet patient needs in hematological conditions. Selexys is also targeting expansion into additional markets, particularly within Europe and certain Asian regions, to increase access to its therapies.

The acquisition offer from Novartis will further strengthen the company’s resources to support these growth initiatives.